Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

Valeriy V. Breder; Бредер Валерий Владимирович; Liudmila G. Zhukova; Жукова Людмила Григорьевна; Larisa V. Bolotina; Болотина Лариса Владимировна; Irina A. Demidova; Демидова Ирина Анатольевна; Yaroslav A. Zhulikov; Жуликов Ярослав Андреевич; Elena V. Lubennikova; Лубенникова Елена Владимировна; David R. Naskhletashvili; Насхлеташвили Давид Романович; Sergey V. Orlov; Орлов Сергей Владимирович; Rashida V. Orlova; Орлова Рашида Вахидовна; Ilya S. Romanov; Романов Илья Станиславович; Nikita A. Savelov; Савелов Никита Александрович; Ksenia A. Sarantseva; Саранцева Ксения Андреевна; Alexandra S. Tyulyandina; Тюляндина Александра Сергеевна; Mikhail Yu. Fedyanin; Федянин Михаил Юрьевич

doi:10.26442/18151434.2023.3.202441

Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

Authors: Breder V.V.¹, Zhukova L.G.², Bolotina L.V.³, Demidova I.A.⁴, Zhulikov Y.A.¹, Lubennikova E.V.¹, Naskhletashvili D.R.¹, Orlov S.V.⁵, Orlova R.V.⁶^,7, Romanov I.S.¹, Savelov N.A.⁴, Sarantseva K.A.¹, Tyulyandina A.S.¹, Fedyanin M.Y.¹^,8^,9
Affiliations:
1. Blokhin National Medical Research Center of Oncology
2. Loginov Moscow Clinical Scientific Center
3. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
4. Moscow City Oncology Hospital №62
5. Pavlov First Saint Petersburg State Medical University
6. Saint Petersburg State University
7. City Oncology Center
8. Moscow Multidisciplinary Clinical Center “Kommunarka”
9. Pirogov National Medical and Surgical Center
Issue: Vol 25, No 3 (2023)
Pages: 295-300
Section: CLINICAL ONCOLOGY
URL: https://journals.rcsi.science/1815-1434/article/view/148893
DOI: https://doi.org/10.26442/18151434.2023.3.202441
ID: 148893

Cite item

Full Text

Abstract
Full Text
About the authors
References
Supplementary files
Statistics

Abstract

NTRK-fusion positive tumors are a rare finding, but targeted therapy demonstrates persistent and sustained systemic and intracranial responses to entrectinib. This resolution proposes algorithms for diagnosing NTRK translocations in various solid tumors and discuses clinical data on the efficacy and safety of entrectinib.

Keywords

NTRK gene fusions, entrectinib, TRK inhibitors, molecular testing in solid tumors, secretory carcinoma

Full Text

##article.viewOnOriginalSite##

About the authors

Valeriy V. Breder

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: vbreder@yandex.ru
ORCID iD: 0000-0002-6244-4294

d. sci. (med.)

Russian Federation, Moscow

Liudmila G. Zhukova

Loginov Moscow Clinical Scientific Center

Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4848-6938

d. sci. (med.), prof. RAS

Russian Federation, Moscow

Larisa V. Bolotina

Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre

Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4879-2687

d. sci. (med.)

Russian Federation, Moscow

Irina A. Demidova

Moscow City Oncology Hospital №62

Email: editor@omnidoctor.ru

cand. sci. (med.)

Russian Federation, Moscow

Yaroslav A. Zhulikov

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4108-439X

oncologist

Russian Federation, Moscow

Elena V. Lubennikova

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-5289-7866

cand. sci. (med.)

Russian Federation, Moscow

David R. Naskhletashvili

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4218-9652

cand. sci. (med.)

Russian Federation, Moscow

Sergey V. Orlov

Pavlov First Saint Petersburg State Medical University

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-6080-8042

d. sci. (med.), prof., corr. member RAS

Russian Federation, Saint Petersburg

Rashida V. Orlova

Saint Petersburg State University; City Oncology Center

Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4447-9458

d. sci. (med.), prof.

Russian Federation, Saint Petersburg

Ilya S. Romanov

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-5421-5985

d. sci. (med.)

Russian Federation, Moscow

Nikita A. Savelov

Moscow City Oncology Hospital №62

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-4164-2240

pathologist

Russian Federation, Moscow

Ksenia A. Sarantseva

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-7817-8429

cand. sci. (med.)

Russian Federation, Moscow

Alexandra S. Tyulyandina

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-6104-7473

d. sci. (med.)

Russian Federation, Moscow

Mikhail Yu. Fedyanin

Blokhin National Medical Research Center of Oncology; Moscow Multidisciplinary Clinical Center “Kommunarka”; Pirogov National Medical and Surgical Center

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-5615-7806

d. sci. (med.)

Russian Federation, Moscow

References

Demetri GD. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022;28(7):1302-12.
Fischer H. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-Oncology. 2020;22(6):819-29.
Krzakowski M. Updated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. J Clin Oncol. 2022;40(16_suppl.):3099.
Lozano-Ortega G. Tumour-specific randomized controlled trials in rare oncogene-driven cancers: asking for the impossible. Personalized & Precision Medicine – Methodological & Statistical Research. 2019;22(3):838-9.
Krebs MG. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 2021;6(2):1-9.
Doebele RC. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021;10(17):1271-82.
Krebs MG, Blay JY, Le Tourneau C, et al. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. ESMO Open. 2021;6(2):1-9.
Brogaart N. Health technology assessment challenges associated with tumour-agnostic therapies: learnings from the assessments of entrectinib and larotrectinib. OHE Consulting Report, London: Office of Health Economics, 2021.
Bowles D. Entrectinib in patients with NTRK fusion-positive (NTRK-fp) thyroid cancer: Updated data from startrk-2. Endocrine Abstracts, 2022.
Goto K. An updated analysis of the clinical efficacy and safety of entrectinib in NTRK fusion-positive (NTRK-fp) sarcoma. Japanese Orthopaedic Association – 54th Annual Musculoskeletal Tumor Meeting, 2021.
Ogale S, Zerbini CEH, Antoniou M, Freund R. A response to "The potential long-term comparative effectiveness of larotrectinib and entrectinib for second-line treatment of trk fusionpositive metastatic lung cancer. J Manag Care Spec Pharm. 2020;26(12):1616-7.
Lu S. Updated analysis of entrectinib in a subset of Chinese (mainland China, Hong Kong, Taiwan) patients with NTRK fusion-positive (fp) solid tumours and ROS1-fp non-small cell lung cancer (NSCLC). ESMO-Asia. 2022:264P.
Murakami H. Entrectinib in Japanese patients with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours. ESMO-ASIA. 2022:390P.
Murphy P. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework. Health Technol Assess. 2021;25(76).
Hechtman JF. NTRK insights: best practices for pathologists. Modern Pathol. 2022;35:298-305.
Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(2):127-40.
Marchiò C, Scaltriti M, Ladanyi M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30(9):1417-27.
Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10-32.
Sohal D, Kennedy EB, Cinar P, et al. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020;38(27):3217-30.
Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-505.
Haddad RD, Bischoff L, Ball D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(8):925-51.
Yoshino T, Pentheroudakis G, Mishima S, et al. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020;31(7):861-72.
Conde E, Hernandez S, Sanchez E, et al. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer. Arch Pathol Lab Med. 2021;145(8):1031-40.
Siozopoulou V, Smits E, De Winne K, et al. NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics (Basel). 2021;11(3):478.
Klug LR, Khosroyani HM, Kent JD, Heinrich MC. New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nat Rew Clin Oncol. 2022;19(5):328-41.